GCM
ESPR

Graham Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Graham Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-71,062
Closed -$195K – 1322
2026
Q1 		$195K Sell
71,062
-90,495
-56% -$286K ﹤0.01% 958
2025
Q4 		$598K Buy
161,557
+146,443
+969% +$473K 0.01% 564
2025
Q3 		$40.1K Buy
+15,114
New +$29.2K ﹤0.01% 1198
2025
Q2 		– Sell
-487,735
Closed -$702K – 1374
2025
Q1 		$702K Buy
487,735
+295,320
+153% +$544K 0.01% 664
2024
Q4 		$423K Sell
192,415
-45,148
-19% -$105K 0.01% 804
2024
Q3 		$392K Sell
237,563
-104,327
-31% -$211K 0.01% 706
2024
Q2 		$759K Buy
+341,890
New +$804K 0.02% 471
2024
Q1 		– Sell
-41,733
Closed -$125K – 1136
2023
Q4 		$125K Sell
41,733
-116,014
-74% -$150K ﹤0.01% 897
2023
Q3 		$155K Buy
+157,747
New +$228K ﹤0.01% 896
2023
Q2 		– Sell
-1,031,068
Closed -$1.64M – 1056
2023
Q1 		$1.64M Buy
1,031,068
+409,894
+66% +$2.12M 0.05% 317
2022
Q4 		$3.87M Buy
+621,174
New +$4.44M 0.12% 94

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Graham Capital Management's ESPR Position: Q2 2026 in Review

Graham Capital Management sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 71,062 shares — an estimated $195K sold.

Graham Capital Management first reported a position in ESPR in Q4 2022 and held it in 11 quarters. The position peaked at $3.87M in Q4 2022. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Graham Capital Management reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Graham Capital Management sold 71,062 Esperion Therapeutics shares in Q2 2026, an estimated $195K.
  • Graham Capital Management first reported a position in Esperion Therapeutics in Q4 2022 and held it in 11 quarters.
  • Graham Capital Management's Esperion Therapeutics position peaked at $3.87M in Q4 2022.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.